Literature DB >> 2415198

Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls.

L Bjerkenstedt, G Edman, L Hagenfeldt, G Sedvall, F A Wiesel.   

Abstract

Compared to healthy controls, unmedicated schizophrenic patients had significantly higher plasma concentrations of taurine, methionine, valine, isoleucine, leucine, phenylalanine, and lysine. Except for taurine, these amino acids share the L-transport system for neutral amino acids. In the patients, homovanillic (HVA) acid levels in CSF were decreased and the plasma levels of the amino acids competing with tyrosine and tryptophan for transport into the brain, were all negatively correlated to the CSF concentrations of HVA and 5-HIAA. These findings could be explained by a change in the affinity of the L-system or by a decrease in its overall capacity in schizophrenia. Raised plasma levels of the competing amino acids may limit the brain uptake of tyrosine, leading to a diminished dopamine turnover, and resulting in a compensatory development of supersensitive dopamine receptors.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2415198     DOI: 10.1192/bjp.147.3.276

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  23 in total

Review 1.  Recent advances in targeting the ionotropic glutamate receptors in treating schizophrenia.

Authors:  Robert E McCullumsmith; John Hammond; Adam Funk; James H Meador-Woodruff
Journal:  Curr Pharm Biotechnol       Date:  2012-06       Impact factor: 2.837

2.  Abnormal expression of glutamate transporter and transporter interacting molecules in prefrontal cortex in elderly patients with schizophrenia.

Authors:  Deborah Bauer; Daya Gupta; Vahram Harotunian; James H Meador-Woodruff; Robert E McCullumsmith
Journal:  Schizophr Res       Date:  2008-08-03       Impact factor: 4.939

Review 3.  Mass spectrometry strategies for clinical metabolomics and lipidomics in psychiatry, neurology, and neuro-oncology.

Authors:  Paul L Wood
Journal:  Neuropsychopharmacology       Date:  2013-07-11       Impact factor: 7.853

Review 4.  Novel nutritional treatment for manic and psychotic disorders: a review of tryptophan and tyrosine depletion studies and the potential of protein-based formulations using glycomacropeptide.

Authors:  Abdulla Badawy
Journal:  Psychopharmacology (Berl)       Date:  2013-07-05       Impact factor: 4.530

5.  Increased concentrations of various amino acids in schizophrenic patients. Evidence for heterozygosity effects?

Authors:  E Smeraldi; A Lucca; F Macciardi; L Bellodi
Journal:  Hum Genet       Date:  1987-06       Impact factor: 4.132

6.  Serum amino acid profiles and dopamine in schizophrenic patients and healthy subjects: Window to the brain?

Authors:  M L Rao; B Strebel; G Gross; G Huber
Journal:  Amino Acids       Date:  1992-02       Impact factor: 3.520

7.  Muscle biopsy findings, conduction velocity and refractory period of single motor nerve fibres in schizophrenia.

Authors:  J Borg; L Edström; L Bjerkenstedt; F A Wiesel; L Farde; L Hagenfeldt
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-12       Impact factor: 10.154

8.  Relationships between clinical effects and monoamine metabolites and amino acids in sulpiride-treated schizophrenic patients.

Authors:  G Alfredsson; F A Wiesel
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

9.  Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment.

Authors:  G Alfredsson; F A Wiesel
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

10.  Peripheral amino Acid levels in schizophrenia and antipsychotic treatment.

Authors:  Vincenzo De Luca; Emanuela Viggiano; Giovanni Messina; Alessandro Viggiano; Carol Borlido; Andrea Viggiano; Marcellino Monda
Journal:  Psychiatry Investig       Date:  2008-12-31       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.